Spots Global Cancer Trial Database for hsp90
Every month we try and update this database with for hsp90 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL | NCT02973399 | Cancer | SNX-5422 plus i... | 18 Years - | Esanex Inc. | |
| Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma | NCT01851096 | Cancer | SNX-5422 | 18 Years - | Esanex Inc. | |
| Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan | NCT01132625 | Advanced Solid ... | AUY922 | 20 Years - | Novartis | |
| Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies | NCT01635712 | Cancer | SNX-5422 | 18 Years - | Esanex Inc. | |
| Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies | NCT01611623 | Cancer | SNX-5422 | 18 Years - | Esanex Inc. | |
| Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors | NCT01892046 | Cancer | SNX-5422 | 18 Years - | Esanex Inc. | |
| A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse | NCT00546780 | Multiple Myelom... | Tanespimycin Bortezomib | 18 Years - | Bristol-Myers Squibb | |
| Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan | NCT01132625 | Advanced Solid ... | AUY922 | 20 Years - | Novartis | |
| A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC] | NCT01714037 | Non-small Cell ... | Debio 0932 Cisplatin Pemetrexed Gemcitabine Docetaxel | 18 Years - | Debiopharm International SA | |
| Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors | NCT01892046 | Cancer | SNX-5422 | 18 Years - | Esanex Inc. | |
| Clinical Trial of Quantitative Detection Kit for Hsp90α in Breast Cancer | NCT02324101 | Breast Cancer | Hsp90 | - | Protgen Ltd | |
| SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) | NCT02008877 | Malignant Perip... Sarcoma | ganetespib Sirolimus | 16 Years - | Sarcoma Alliance for Research through Collaboration | |
| A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma | NCT00514371 | Multiple Myelom... | tanespimycin Bortezomib | 18 Years - | Bristol-Myers Squibb | |
| Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL | NCT02973399 | Cancer | SNX-5422 plus i... | 18 Years - | Esanex Inc. | |
| Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma | NCT01851096 | Cancer | SNX-5422 | 18 Years - | Esanex Inc. | |
| Clinical Trial of Quantitative Detection Kit for Hsp90α in Hepatic Cancer | NCT02324127 | Liver Cancer | hsp90 | - | Protgen Ltd | |
| A Study of HS-196, an HSP90 Inhibitor-linked NIR Probe for Solid Malignancies | NCT03333031 | Solid Tumor | HS-196 | 18 Years - 99 Years | Duke University | |
| Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors | NCT02063958 | Cancer | SNX-5422 | 18 Years - | Esanex Inc. | |
| Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors | NCT01892046 | Cancer | SNX-5422 | 18 Years - | Esanex Inc. | |
| Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors | NCT02063958 | Cancer | SNX-5422 | 18 Years - | Esanex Inc. | |
| Safety and Activity of SNX-5422 Plus Ibrutinib in CLL | NCT02914327 | Cancer | SNX-5422 plus i... | 18 Years - | Esanex Inc. | |
| An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations | NCT01646125 | Advanced Non Sm... | AUY922 Docetaxel Pemetrexed | 18 Years - | Novartis | |
| Clinical Trial of Quantitative Detection Kit for Hsp90α in Breast Cancer | NCT02324101 | Breast Cancer | Hsp90 | - | Protgen Ltd | |
| A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC] | NCT01714037 | Non-small Cell ... | Debio 0932 Cisplatin Pemetrexed Gemcitabine Docetaxel | 18 Years - | Debiopharm International SA | |
| An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations | NCT01646125 | Advanced Non Sm... | AUY922 Docetaxel Pemetrexed | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
